Use of GLP

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-18T16:00:18.143Z • Permanent link

Amit Singhal, the CEO of Allergan, announced in March that the pharmaceutical giant would discontinue the sale of its weight loss medication, Contrave, in the United States. The move was seen as a significant blow to the company's business, with Contrave generating $1 billion in revenue in 2016. The decision was made due to declining sales, which were attributed to a combination of factors, including increased competition from generic alternatives and growing concerns over the medication's effectiveness.

In response to the announcement, the European Medicines Agency (EMA) began investigating reports of liver damage associated with Contrave. The agency found that a small percentage of patients taking the medication had experienced severe liver damage, leading to liver failure and even death. The EMA subsequently tightened its regulations on the sale of Contrave in the EU, requiring manufacturers to include more detailed warnings about the medication's risks.

Meanwhile, pharmaceutical companies such as Novo Nordisk and Pfizer were capitalizing on the trend towards weight loss medications. Novo Nordisk's semaglutide-based medication, Ozempic, has seen significant growth in sales, particularly in the US, where it is used to treat type 2 diabetes. Pfizer's Lipitor, a statin medication, has also seen increased sales, as it has been shown to have benefits for weight loss in addition to its cholesterol-lowering properties.

The decision by Allergan to discontinue Contrave has significant implications for the data sources used to track weight loss medications. Companies such as MarketWatch and Bloomberg rely on data from pharmaceutical companies like Allergan to inform their reporting on the market. The loss of Contrave data will likely lead to a decline in the accuracy of these reports, making it more difficult for investors and researchers to make informed decisions.

Regulatory bodies such as the FDA will also be impacted by the decision. The agency will need to adjust its guidelines and regulations to reflect the changing landscape of weight loss medications. This may involve revising the way the agency evaluates the safety and efficacy of these medications, as well as updating its guidelines for prescribing and monitoring them.

The decision by Allergan to discontinue Contrave is part of a larger trend towards increased regulation of pharmaceutical companies. In recent years, there have been several high-profile cases of pharmaceutical companies facing lawsuits and fines over the safety and efficacy of their products. This has led to increased scrutiny of the industry and a growing demand for greater transparency and accountability.